Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients
- 111 Downloads
Fish oil has been recently proposed as a possible effective treatment in inflammatory bowel disease (IBD); however, a lot of annoying side effects (ie, belching, halitosis, diarrhea, etc) affect patient compliance. We carried out a study of patient tolerance in a group of Crohn's disease (CD) patients with a new fish oil derivative consisting of 500-mg capsules of eicosapentaenoic-docosahexaenoic (EPA 40%-DHA 20%), a free fatty acid mixture (Purepa), and we also evaluated its incorporation into phospholipids, both in plasma and in red cell membranes. Five groups of 10 CD patients in remission received nine Purepa capsules daily in four different preparations (A: uncoated, B: coated, pH 5.5; C: coated, pH 5.5, 60 min time release; D: coated, pH 6.9) and 12 × 1-g capsules daily of a triglyceride preparation (Max-EPA, EPA 18%-DHA 10%), respectively. We coated three of the four Purepa preparations in order to delay the release of contents in an attempt to minimize the side effects. After six weeks of treatment, the group taking Purepa capsules, coated, pH 5.5, 60 min time release (group C) showed the best incorporation of EPA and DHA in red blood cell phospholipid membranes (EPA from 0.2 to 4.4%, DHA from 3.7 to 6.3%), and no side effects were registered, whereas in all other groups side effects were experienced in 50% or more of subjects. This new preparation will make it possible to treat patients for long periods.
Key wordsCrohn's disease fish oil
Unable to display preview. Download preview PDF.
- 3.Bittiner SB, Tucker WF, Cartwright I, Bleehen SS: A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet i:378–380, 1988Google Scholar
- 4.Lee TH, Hoover RL, Williams D, Sperling RI, Ravalese J, Hoover RL, Mouse F, Coblyn JS, Fraser PA, Spur BW, Robinson DR, Lewis RA, Austen KF: Effect of dietary enrichment with eicosapentaenoic acid and docosahexaenoic acids onin vitro polymorphonuclear and monocyte leukotriene generation and polymorphonuclear leukocyte function. N Engl J Med 312:1217–1224, 1985PubMedGoogle Scholar
- 8.Weber PC: The modification of the arachidonic acid cascade by n-3 fatty acids. Adv Prostaglandin Thromboxane Leukotriene Res 20:232–240, 1990Google Scholar
- 9.Sinclair HM: The diet of Canadian Indians and Eskimos. Proc Nutr Soc 12(1):69, 1953Google Scholar
- 10.Tobin A: Fish oil supplementation in pregnancy. Lancet 340:118, 1992Google Scholar
- 23.Dodge JT, Phillips GB: Composition of phospholipids and phospholipid fatty acids and aldehydes in human red cells. J Lipids Res 8:667–675, 1967Google Scholar
- 24.Rouser G, Kritcheusky G, Yamamoto A:In Lipid Chromatographic Analysis: Chromatography of Common and Uncommon Lipid Classes. GV Marinetti, New York, Marcel Dekker, 1967, p 99Google Scholar
- 25.Morrison WR, Smith LM: Preparation of fatty acids methyl esters and dimethylacetals. J Lipids Res 5:600–608, 1964Google Scholar
- 26.Galloway JH, Cartwright IJ, Woodcock BE, Greaves M, Russel RGG, Preston FE: Effects of dietary fish oil supplementation on the fatty acid composition of the human platelet membrane: demonstration of selectivity in the incorporation of eicosapentaenoic acid into membrane phospholipid pools. Clin Sci 68:449–454, 1985PubMedGoogle Scholar
- 29.Belluzzi A, Hawthorne AB, Hawkey CJ: Increased neutrophil membrane w-3 fatty acids may be of clinical benefit in patients with ulcerative colitis. Gut A-1501–A-1502, 1989 (abstract)Google Scholar